Urinary metabolomics reveals alterations of aromatic amino acid metabolism of alzheimer’s disease in the transgenic CRND8 mice

Current Alzheimer Research

Volumn 13, Issue 7, 2016, Pages 764-776

  Tang, Zhi ^a   Liu, Liangfeng ^a   Li, Yongle ^b   Dong, Jiyang ^c   Li, Min ^a   Huang, Jiandong ^d   Lin, Shuhai ^a   Cai, Zongwei ^a  

^a HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^b Shenzhen Academy of Metrology and Quality Inspection   (China)

^c XIAMEN UNIVERSITY   (China)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Alzheimer s disease; Mass spectrometry; Metabolomics; Noninvasive analysis; Transgenic CRND8; Tryptophan metabolism; Urine

Indexed keywords

3 O METHYLDOPA; AROMATIC AMINO ACID; AROMATIC LEVO AMINO ACID DECARBOXYLASE; GLYCINE; KYNURENINE; N ACETYLVANILALANINE; SEROTONIN; TRYPTOPHAN; UNCLASSIFIED DRUG; AMYLOID PRECURSOR PROTEIN;

ALZHEIMER DISEASE; AMINO ACID METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBON METABOLISM; CITRIC ACID CYCLE; CONTROLLED STUDY; DNA MODIFICATION; DOWN REGULATION; FEMALE; HYDROPHILIC INTERACTION CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; METABOLOME; METABOLOMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRYPTOPHAN METABOLISM; UPREGULATION; URINALYSIS; URINE; AGE; ANIMAL; DISEASE MODEL; GENETICS; HUMAN; METABOLIC DISEASES; METABOLISM; MULTIVARIATE ANALYSIS; MUTATION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

AGE FACTORS; ALZHEIMER DISEASE; AMINO ACIDS, AROMATIC; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MASS SPECTROMETRY; METABOLIC DISEASES; METABOLOMICS; MICE, TRANSGENIC; MULTIVARIATE ANALYSIS; MUTATION; SIGNAL TRANSDUCTION;

EID: 84974739709     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205013666160129095340     Document Type: Article

References (66)

1. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement 9(1): 63-75 e2 (2013).
2. Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell 148(6): 1204-22 (2012).
3. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297(5580): 353-6 (2002).
4. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr., Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7(3): 263-9 (2011).
5. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7(3): 280-92 (2011).
6. Fiandaca MS, Mapstone ME, Cheema AK, Federoff HJ. The critical need for defining preclinical biomarkers in Alzheimer's disease. Alzheimers Dement 10(3): S196-212 (2014).
7. Trushina E, Mielke MM. Recent advances in the application of metabolomics to Alzheimer's Disease. Biochim Biophys Acta 1842(8): 1232-9 (2014).
8. Oresic M, Hyotylainen T, Herukka SK, Sysi-Aho M, Mattila I, Seppanan-Laakso T, et al. Metabolome in progression to Alzheimer's disease. Transl Psychiatry 1: e57 (2011).
9. Wang G, Zhou Y, Huang FJ, Tang HD, Xu XH, Liu JJ, et al. Plasma metabolite profiles of Alzheimer's disease and mild cognitive impairment. J Proteome Res 13(5): 2649-58 (2014).
10. Salek RM, Xia J, Innes A, Sweatman BC, Adalbert R, Randle S, et al. A metabolomic study of the CRND8 transgenic mouse model of Alzheimer's disease. Neurochem Int 56(8): 937-47 (2010).
11. Trushina E, Dutta T, Persson XM, Mielke MM, Petersen RC. Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer's disease using metabolomics. PloS one 8(5): e63644 (2013).
12. Trushina E, Nemutlu E, Zhang S, Christensen T, Camp J, Mesa J, et al. Defects in mitochondrial dynamics and metabolomic signatures of evolving energetic stress in mouse models of familial Alzheimer's disease. PloS One 7(2): e32737 (2012).
13. Lin S, Liu H, Kanawati B, Liu L, Dong J, Li M, et al. Hippocampal metabolomics using ultrahigh-resolution mass spectrometry reveals neuroinflammation from Alzheimer's disease in CRND8 mice. Anal Bioanal Chem 405(15): 5105-17 (2013).
14. Lin S, Kanawati B, Liu L, Witting M, Li M, Huang J, et al. Ultrahigh resolution mass spectrometry-based metabolic characterization reveals cerebellum as a disturbed region in two animal models. Talanta 118: 45-53 (2014).
15. Peng J, Guo K, Xia J, Zhou J, Yang J, Westaway D, et al. Development of isotope labeling liquid chromatography mass spectrometry for mouse urine metabolomics: quantitative metabolomic study of transgenic mice related to Alzheimer's disease. J Proteome Res 13(10): 4457-69 (2014).
16. Fukuhara K, Ohno A, Ota Y, Senoo Y, Maekawa K, Okuda H, et al. NMR-based metabolomics of urine in a mouse model of Alzheimer's disease: identification of oxidative stress biomarkers. J Clin Biochem Nutr 52(2): 133-8 (2013).
17. Chishti MA, Yang DS, Janus C, Phinney AL, Horne P, Pearson J, et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem 276(24): 21562-70 (2001).
18. Durairajan SS, Liu LF, Lu JH, Chen LL, Yuan Q, Chung SK, et al. Berberine ameliorates beta-amyloid pathology, gliosis, and cognitive impairment in an Alzheimer's disease transgenic mouse model. Neurobiol Aging 33(12): 2903-19 (2012).
19. Yuan Q, Su H, Chau WH, Toa Ng C, Huang JD, Wu W, et al. Behavioral stress fails to accelerate the onset and progression of plaque pathology in the brain of a mouse model of Alzheimer's disease. PloS One 8(1): e53480 (2013).
20. Zwilling D, Huang SY, Sathyasaikumar KV, Notarangelo FM, Guidetti P, Wu HQ, et al. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 145(6): 863-74 (2011).
21. Broderick G, Craddock TJ. Systems biology of complex symptom profiles: capturing interactivity across behavior, brain and immune regulation. Brain Behav Immun 29: 1-8 (2013).
22. Abdenur JE, Abeling N, Specola N, Jorge L, Schenone AB, van Cruchten AC, et al. Aromatic l-aminoacid decarboxylase deficiency: unusual neonatal presentation and additional findings in organic acid analysis. Mol Genet Metab 87(1): 48-53 (2006).
23. Francis BM, Yang J, Hajderi E, Brown ME, Michalski B, McLaurin J, et al. Reduced tissue levels of noradrenaline are associated with behavioral phenotypes of the TgCRND8 mouse model of Alzheimer's disease. Neuropsychopharmacology 37(8): 1934-44 (2012).
24. Calvani R, Brasili E, Pratico G, Capuani G, Tomassini A, Marini F, et al. Fecal and urinary NMR-based metabolomics unveil an aging signature in mice. Exp Gerontol 49: 5-11 (2014).
25. Luan H, Liu LF, Meng N, Tang Z, Chua KK, Chen LL, et al. LCMS-Based Urinary Metabolite Signatures in Idiopathic Parkinson's Disease. J Proteome Res 14(1): 467-78 (2015).
26. Di Stefano G, Manerba M, Vettraino M. NAD metabolism and functions: a common therapeutic target for neoplastic, metabolic and neurodegenerative diseases. Curr Top Med Chem 13(23): 2918-29 (2013).
27. Rodriguez JJ, Noristani HN, Verkhratsky A. The serotonergic system in ageing and Alzheimer's disease. Prog Neurobiol 99(1): 15-41 (2012).
28. Ruddick JP, Evans AK, Nutt DJ, Lightman SL, Rook GA, Lowry CA. Tryptophan metabolism in the central nervous system: medical implications. Expert Rev Mol Med 8(20): 1-27 (2006).
29. Bachurin S, Oxenkrug G, Lermontova N, Afanasiev A, Beznosko B, Vankin G, et al. N-acetylserotonin, melatonin and their derivatives improve cognition and protect against beta-amyloid-induced neurotoxicity. Ann N Y Acad Sci 890: 155-66 (1999).
30. Heyes MP, Saito K, Crowley JS, Davis LE, Demitrack MA, Der M, et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 115 (Pt 5): 1249-73 (1992).
31. Morris MC, Evans DA, Bienias JL, Scherr PA, Tangney CC, Hebert LE, et al. Dietary niacin and the risk of incident Alzheimer's disease and of cognitive decline. J Neurol Neurosurg Psychiatry 75(8): 1093-9 (2004).
32. Roberts KM, Fitzpatrick PF. Mechanisms of tryptophan and tyrosine hydroxylase. IUBMB life 65(4): 350-7 (2013).
33. Murr C, Widner B, Wirleitner B, Fuchs D. Neopterin as a marker for immune system activation. Curr Drug Metab 3(2): 175-87 (2002).
34. Casal JA, Robles A, Tutor JC. Serum markers of monocyte/ macrophage activation in patients with Alzheimer's disease and other types of dementia. Clin Biochem 36(7): 553-6 (2003).
35. Selmer T, Andrei PI. p-Hydroxyphenylacetate decarboxylase from Clostridium difficile. A novel glycyl radical enzyme catalysing the formation of p-cresol. Eur J Biochem 268(5): 1363-72 (2001).
36. Lesaffer G, De Smet R, Belpaire FM, Van Vlem B, Van Hulle M, Cornelis R, et al. Urinary excretion of the uraemic toxin p-cresol in the rat: contribution of glucuronidation to its metabolization. Nephrol Dial Transplant 18(7): 1299-306 (2003).
37. Holmes E, Li JV, Athanasiou T, Ashrafian H, Nicholson JK. Understanding the role of gut microbiome-host metabolic signal disruption in health and disease. Trends Microbiol 19(7): 349-59 (2011).
38. Diaz Heijtz R, Wang S, Anuar F, Qian Y, Bjorkholm B, Samuelsson A, et al. Normal gut microbiota modulates brain development and behavior. Proc Natl Acad Sci U S A 108(7): 3047-52 (2011).
39. Hsiao EY, McBride SW, Hsien S, Sharon G, Hyde ER, McCue T, et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell 155(7): 1451-63 (2013).
40. Borre YE, O'Keeffe GW, Clarke G, Stanton C, Dinan TG, Cryan JF. Microbiota and neurodevelopmental windows: implications for brain disorders. Trends Mol Med 20(9): 509-18 (2014).
41. Wang Y, Kasper LH. The role of microbiome in central nervous system disorders. Brain Behav Immun 38: 1-12 (2014).
42. Chen Z, Zhong C. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. Prog Neurobiol 108: 21-43 (2013).
43. Mosconi L, Pupi A, De Leon MJ. Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease. Ann N Y Acad Sci 1147: 180-95 (2008).
44. Gallant M, Rak M, Szeghalmi A, Del Bigio MR, Westaway D, Yang J, et al. Focally elevated creatine detected in amyloid precursor protein (APP) transgenic mice and Alzheimer disease brain tissue. J Biol Chem 281(1): 5-8 (2006).
45. Gibson GE, Sheu KF, Blass JP, Baker A, Carlson KC, Harding B, et al. Reduced activities of thiamine-dependent enzymes in the brains and peripheral tissues of patients with Alzheimer's disease. Arch Neurol 45(8): 836-40 (1988).
46. Butterworth RF, Besnard AM. Thiamine-dependent enzyme changes in temporal cortex of patients with Alzheimer's disease. Metab Brain Dis 5(4): 179-84 (1990).
47. Mastrogiacomo F, Bergeron C, Kish SJ. Brain alpha-ketoglutarate dehydrogenase complex activity in Alzheimer's disease. J Neurochem 61(6): 2007-14 (1993).
48. Gibson GE, Zhang H, Sheu KF, Bogdanovich N, Lindsay JG, Lannfelt L, et al. Alpha-ketoglutarate dehydrogenase in Alzheimer brains bearing the APP670/671 mutation. Ann Neurol 44(4): 676-81 (1998).
49. Dumont M, Ho DJ, Calingasan NY, Xu H, Gibson G, Beal MF. Mitochondrial dihydrolipoyl succinyltransferase deficiency accelerates amyloid pathology and memory deficit in a transgenic mouse model of amyloid deposition. Free Radic Biol Med 47(7): 1019-27 (2009).
50. Dumont M, Wille E, Stack C, Calingasan NY, Beal MF, Lin MT. Reduction of oxidative stress, amyloid deposition, and memory deficit by manganese superoxide dismutase overexpression in a transgenic mouse model of Alzheimer's disease. FASEB J 23(8): 2459-66 (2009).
51. Pocernich CB, Butterfield DA. Elevation of glutathione as a therapeutic strategy in Alzheimer disease. Biochim Biophys Acta 1822(5): 625-30 (2012).
52. Bennett MJ, Powell S, Swartling DJ, Gibson KM. Tiglylglycine excreted in urine in disorders of isoleucine metabolism and the respiratory chain measured by stable isotope dilution GC-MS. Clin Chem 40(10): 1879-83 (1994).
53. Papes F, Surpili MJ, Langone F, Trigo JR, Arruda P. The essential amino acid lysine acts as precursor of glutamate in the mammalian central nervous system. FEBS Lett 488(1-2): 34-8 (2001).
54. Brown DD, Kies MW. The mammalian metabolism of L-histidine. I. The enzymatic formation of L-hydantion-5-propionic acid. J Biol Chem 234: 3182-7 (1959).
55. Zhang Y, Zhu X, Torelli AT, Lee M, Dzikovski B, Koralewski RM, et al. Diphthamide biosynthesis requires an organic radical generated by an iron-sulphur enzyme. Nature 465(7300): 891-6 (2010).
56. Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 55(11): 1449-55 (1998).
57. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 346(7): 476-83 (2002).
58. James SJ, Cutler P, Melnyk S, Jernigan S, Janak L, Gaylor DW, et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr 80(6): 1611-7 (2004).
59. Hershfield MS, Krodich NM. S-adenosylhomocysteine hydrolase is an adenosine-binding protein: a target for adenosine toxicity. Science 202(4369): 757-60 (1978).
60. Fuso A, Seminara L, Cavallaro RA, D'Anselmi F, Scarpa S. Sadenosylmethionine/ homocysteine cycle alterations modify DNA methylation status with consequent deregulation of PS1 and BACE and beta-amyloid production. Mol Cell Neurosci 28(1): 195-204 (2005).
61. Smith MA, Hirai K, Hsiao K, Pappolla MA, Harris PL, Siedlak SL, et al. Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem 70(5): 2212-5 (1998).
62. Hallen A, Jamie JF, Cooper AJ. Lysine metabolism in mammalian brain: an update on the importance of recent discoveries. Amino Acids 45(6): 1249-72 (2013).
63. Hensley K, Christov A, Kamat S, Zhang XC, Jackson KW, Snow S, et al. Proteomic identification of binding partners for the brain metabolite lanthionine ketimine (LK) and documentation of LK effects on microglia and motoneuron cell cultures. J Neurosci 30(8): 2979-88 (2010).
64. Tuppo EE, Forman LJ, Spur BW, Chan-Ting RE, Chopra A, Cavalieri TA. Sign of lipid peroxidation as measured in the urine of patients with probable Alzheimer's disease. Brain Res Bull 54(5): 565-8 (2001).
65. Pratico D, Clark CM, Liun F, Rokach J, Lee VY, Trojanowski JQ. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch Neurol 59(6): 972-6 (2002).
66. Cui Y, Liu X, Wang M, Liu L, Sun X, Ma L, et al. Lysophosphatidylcholine and amide as metabolites for detecting alzheimer disease using ultrahigh-performance liquid chromatographyquadrupole time-of-flight mass spectrometry-based metabonomics. J Neuropathol Exp Neurol 73(10): 954-63 (2014).